General Medicine Flashcards
(212 cards)
specificity
rule out a disease
sensitivity
rule in a disease
what happens to ppv and npv as prevalence increases
ppv increases and npv decreases
how does affect sensitivity and specificity
it doesn’t only predictive value
Influenza vaccine
Live attenuated, inactivated, recombinant
One dose annually (for all persons ≥18 y), including pregnant women and those with HIV infection
Tetanus, diphtheria, and pertussis
Inactivated, One dose Tdap, then Td booster every 10 y for all adults; one dose Tdap each pregnancy between 27 to 36 weeks’ gestation
Varicella
Live attenuated; For all immunocompetent persons lacking immunity
Herpes zoster
Recombinant
All nonimmunocompromised persons age ≥50 y, including those previously vaccinated with the inactivated vaccine
HPV
Inactivated; Women aged 19-26 y; men aged 11-21 y; men aged 22-26 y who are immunocompromised or who have sex with other men
MMR
Live attenuated
Adults born in 1957 or later without evidence of vaccination or immunity
Meningococcal (MenACWY)
Inactivated, First-year college students residing in dormitories, travelers to endemic areas, military recruits, and exposed persons; asplenia or complement deficiencies; boost
every 5 y if risk remains
Hepatitis A
Inactivated, Any adult requesting immunization and those at high risk
Hepatitis B
Inactivated, Any adult requesting immunization and those at high risk
PNA vaccine
Immunocompetent adults age ≥65
PCV 13
PCV 23, one year after 13
Revaccination after 5 years with PCV 23 only if vaccinated before 65
PNA vaccine in Immunocompetent persons with chronic heart, lung, or liver disease, diabetes mellitus, alcoholism, cigarette smoking
PCV 23 only
Revaccination after 5 years with PCV 23 only if vaccinated before 65
PNA vaccine in Persons with functional (sickle cell disease, hemoglobinopathies) or anatomic asplenia
PCV 13
PCV 23
Revaccination after 5 years with PCV 23
PNA vaccine in Immunocompromised persons with HIV, chronic kidney disease, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, multiple myeloma, generalized malignancy, taking immunosuppressant drugs, congenital immunodeficiencies, solid organ transplant
PCV 13
PCV 23
Revaccination after 5 years with PCV 23
PNA vaccine in CSF leaks or cochlear implants
PCV 13
PCV 23, but no revaccination!
indication for asa therapy for primary prevention
adults aged 50-59 years • 10-year CVD risk ≥10% • life expectancy ≥10 years • no increased risk for bleeding • willing to take low-dose aspirin daily ≥10 years
AAA screening
One-time abdominal ultrasonography in all men ages 65-75 y who have ever smoked;
selectively screen men ages 65-75 y who have never smoked
Depression screening
all adults
Diabetes mellitus screening
Ages 40-70 y who are overweight or obese as part of risk assessment for cardiovascular disease
Hypertension screening
All adults; obtain measurements outside of the clinical setting for diagnostic confirmation before
starting treatment
Lipid disorders screening
Universal lipid screening in adults aged 40-75 y as part of risk assessment for cardiovascular
disease